Cargando…

Comparison of novel oncology drugs that received dual approval from the US accelerated approval and EU conditional marketing authorisation pathways, 2006–2021: a cross-sectional study

OBJECTIVE: We aimed to provide insight into differences in drug review decisions made by the US Food and Drug Administration’s (FDA) accelerated approval (AA) pathway and the European Medicines Agency’s (EMA) conditional marketing authorisation (CMA) pathway, and to add to the current knowledge base...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Jinping, Li, Jinlian, Liu, Yue, Wang, Haoyang, Wang, Yifei, Yang, Yifan, Chen, Yi, Jiang, Rong, Shao, Rong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Health Policy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10255285/ https://www.ncbi.nlm.nih.gov/pubmed/37286329 http://dx.doi.org/10.1136/bmjopen-2022-069132

Ejemplares similares

Quality of evidence considered by Health Canada in granting full market authorisation to new drugs with a conditional approval: a retrospective cohort study
por: Lexchin, Joel
Publicado: (2018)

Marketing authorisation and pricing of FDA-approved cancer drugs in Brazil: a retrospective analysis
por: Ivama-Brummell, Adriana M., et al.
Publicado: (2023)

Time to market for drugs approved in Canada between 2014 and 2018: an observational study
por: Lexchin, Joel
Publicado: (2021)

Market competition among manufacturers of novel high-risk therapeutic devices receiving FDA premarket approval between 2001 and 2018
por: Rathi, Vinay K, et al.
Publicado: (2023)

Clinical development time is shorter for new anticancer drugs approved via accelerated approval in the US or via conditional approval in the EU
por: Demirci, Ebru, et al.
Publicado: (2023)

Approvals in 2021: dangling Accelerated Approvals, drug dosing, new approvals and beyond
por: Lemery, Steven, et al.
Publicado: (2022)

A New Approach to Psychiatric Drug Approval in Europe
por: Barbui, Corrado, et al.
Publicado: (2013)

Impact of Regulatory Approval Status on CADTH Reimbursement of Oncology Drugs and Role of Real-World Evidence on Conditional Approvals from 2019 to 2021
por: Lau, Catherine, et al.
Publicado: (2022)

Drug approval status and recommendations for listing on public formularies: a Canadian cohort analysis
por: Lexchin, Joel
Publicado: (2017)

EU Regulatory Pathways for ATMPs: Standard, Accelerated and Adaptive Pathways to Marketing Authorisation
por: Detela, Giulia, et al.
Publicado: (2019)

The European Medicines Agency's EU conditional marketing authorisations for COVID-19 vaccines
por: Cavaleri, Marco, et al.
Publicado: (2021)

Europe Needs a Central, Transparent, and Evidence-Based Approval Process for Behavioural Prevention Interventions
por: Faggiano, Fabrizio, et al.
Publicado: (2014)

Association of expedited review programmes with postmarketing safety events of new drugs approved by the US food and drug administration between 2007 and 2017
por: Zhu, Xingyue, et al.
Publicado: (2022)

Oncologic orphan drugs approved in the EU – do clinical trial data correspond with real-world effectiveness?
por: Schuller, Yvonne, et al.
Publicado: (2018)

Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US and Europe From 2007 to 2021
por: Vokinger, Kerstin N., et al.
Publicado: (2022)

Leveraging existing opportunities for improved Orphan Drug approval in the EU
por: Edfjäll, Catarina
Publicado: (2012)

US Supercollider approved
Publicado: (1987)

Characteristics of Postmarketing Studies for Vaccines Approved by the US Food and Drug Administration, 2006-2020
por: Moneer, Osman, et al.
Publicado: (2021)

2015 Review of Newly Approved Oncologic Therapies
por: Medina, Patrick, et al.
Publicado: (2016)

Patient-Reported Outcome Measures in Oncology Drugs Approved by the European Medicines Agency, 2017-2021
por: Ciani, Oriana, et al.
Publicado: (2023)

Assessing the potential clinical impact of reciprocal drug approval legislation on access to novel therapeutics in the USA: a cohort study
por: Larochelle, Matthieu, et al.
Publicado: (2017)

Approvals and Timing of New Formulations of Novel Drugs Approved by the US Food and Drug Administration Between 1995 and 2010 and Followed Through 2021
por: Gupta, Ravi, et al.
Publicado: (2022)

Marketing approval of mogamulizumab: A triumph for glyco-engineering
por: Beck, Alain, et al.
Publicado: (2012)

Drug-loaded erythrocytes: on the road toward marketing approval
por: Bourgeaux, Vanessa, et al.
Publicado: (2016)

Utilization and Comparative Effectiveness of Caspofungin and Voriconazole Early after Market Approval in the U.S
por: Ascioglu, Sibel, et al.
Publicado: (2014)

Expediting approval for medical countermeasures to address high burden disease: an ethical justification to move beyond emergency use authorisation
por: Mercuri, Mathew, et al.
Publicado: (2023)

Biosimilar agents in oncology/haematology: from approval to practice
por: Niederwieser, Dietger, et al.
Publicado: (2011)

Radiation Oncology Device Approval in the United States and Canada
por: Beers, Craig A, et al.
Publicado: (2019)

Estimation of Value-Based Price for Five High-Technology Medical Devices Approved by a Regional Health Technology Assessment Committee in Italy
por: Messori, Andrea, et al.
Publicado: (2022)

Prescription Drugs Marketed in the United States Should Be Approved by the FDA
por: Shepherd, Marvin
Publicado: (2003)

US FDA-approved therapeutic antibodies with high-concentration formulation: summaries and perspectives
por: Wang, Shawn Shouye, et al.
Publicado: (2021)

Herpes Zoster Vaccination Rates in Hematological and Oncological Patients—Stock Taking 2 Years after Market Approval
por: Kiderlen, Til Ramón, et al.
Publicado: (2022)

Statistical Considerations on the Use of RWD/RWE for Oncology Drug Approvals: Overview and Lessons Learned
por: Ro, Sunhee K., et al.
Publicado: (2023)

Trends and Characteristics of New Drug Approvals in China, 2011–2021
por: Su, Ling, et al.
Publicado: (2022)

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021
por: Kayki-Mutlu, Gizem, et al.
Publicado: (2022)

Contemporary oncology trials, drug approvals and the physician-patient relationship
por: Schnog, John-John B., et al.
Publicado: (2022)

Single-arm trials for domestic oncology drug approvals in China
por: Zhang, Hong, et al.
Publicado: (2023)

Pre‐approval and post‐approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe: A comparison with standard approved cancer drugs
por: Bloem, Lourens T., et al.
Publicado: (2022)

Winning approval
por: Schopper, Herwig Franz
Publicado: (2004)

Approved Minutes
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_951dg61i7obh9sjq8qtg2puv8c